, Volume 16, Issue 4, pp 620-639
Date: 29 May 2009

Applications of optical coherence tomography in cardiovascular medicine, Part 2

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Drug Eluting Stents and Oct

Introduction

Despite the concerns raised by a well-publicized presentation at the World Congress of Cardiology (WCC) meeting in September 2006,1 Drug Eluting Stents (DES) have approximately the same short-term and long-term safety profile as Bare Metal Stents (BMS) when used for FDA-labeled indications.2-5 DES have an in-stent thrombosis rate of 3.6% within 4 years6 compared to a 3.3% rate for BMS. The main disadvantage of DES is the rate of late complications, specifically stent thrombosis.4 This usually occurs after the first year and is usually associated with discontinuation of antiplatelet therapy.7,8 The main benefit of DES is the decreased need for target vessel revascularization,4 which is enough to be of a clinical advantage in recommending the continued use of DES.9

However, there are still some issues that remain to be resolved with DES. The ideal amount of anti-proliferative drug and polymer which strikes the ideal balance between excess neointima f

The authors, JWV and ASP, have received funding from NIH under Grant # HL07446 and 5R01EY016462, respectively, DAV has received financial support as ‘The Palmaz Gift to the MD/PhD program at UTHSCSA’, and MFD from the VA Merit.